Search results for "CHOD"

showing 10 items of 372 documents

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations

2007

This randomised, double-blind, 6-month study compared budesonide/formoterol for maintenance and relief with salmeterol/fluticasone and a fixed maintenance dose of budesonide/formoterol, both with terbutaline for relief. Following a 2-week run-in, 3335 symptomatic adults and adolescents (mean FEV1 73% predicted, mean inhaled corticosteroid dose 745 μg/day) received budesonide/formoterol 160/4.5 μg one inhalation bid plus additional inhalations as needed, salmeterol/fluticasone 25/125 μg two inhalations bid plus as-needed terbutaline or budesonide/formoterol 320/9 μg one inhalation bid plus as-needed terbutaline. Budesonide/formoterol for maintenance and relief prolonged the time to first sev…

Budesonidemedicine.drug_classbusiness.industryTerbutalineGeneral Medicinerespiratory systemrespiratory tract diseasesBudesonide/formoterolimmune system diseasesBronchodilatorAnesthesiamedicineFormoterol FumarateFormoterolSalmeterolbusinesshormones hormone substitutes and hormone antagonistscirculatory and respiratory physiologymedicine.drugFluticasoneInternational Journal of Clinical Practice
researchProduct

24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma

2015

Background: Once-daily tiotropium Respimat® (tioR) add-on therapy has demonstrated efficacy in patients with moderate symptomatic asthma. Aim and Objectives: To investigate whether dosing regimen (QD vs BID) affected 24-h bronchodilator efficacy and exposure of tioR. Methods: 2 randomised, double-blind, crossover trials (trial 1, NCT01152450 [placebo-controlled]; trial 2, NCT01696071); 4-week treatments of tioR 5 µg QD, 2.5 µg BID and placebo Respimat® (pboR) added to medium-dose ICS (400-800 µg budesonide or equivalent). Primary end point (Week 4): area under the curve response for FEV1 (FEV1 AUC(0-24h)) (trial 1, tioR vs pboR; trial 2, QD vs BID). Pharmacokinetic end points (steady state)…

Budesonidemedicine.medical_specialtyRespimatmedicine.drug_classbusiness.industryArea under the curvePlaceboGastroenterologyPharmacokineticsInternal medicineBronchodilatormedicineClinical endpointDosingbusinessmedicine.drug5.3 Allergy and Immunology
researchProduct

Ikonoklazm – spór religijny czy polityczny? Leona III idea obrony czystości wiary i uniformizacji państwa

2017

W historii kultu obrazów oraz jego właściwego pojmowania zrodził się w starożytności ruch, który – zgodnie z tradycją starotestamentową – sprzeciwiał się takiej formie pobożności. Reformy ikonoklastyczne, zapoczątkowane przez kalifa Jazyda II, zyskiwały coraz szersze poparcie w kręgach chrześcijańskich, szczególnie wśród monofiytów. Autor wskazuje nie tylko na aspekty teologiczne sporu o obrazy w VIII w., ale także naświetla problem jego politycznego wykorzystania przez cesarza Leona III, dążącego (po częściowym odzyskaniu ziem Bizancjum spod panowania islamskiego) do uniformizacji państwa i chrześcijaństwa. Po naszkicowaniu ogólnej sytuacji politycznej, autor przedstawia zarzuty, jakie cec…

Byzantium in VIII c.unification of the Eastern EmpireiconoclasmChristian world and IslamLeo III the Isaurianzjednoczenie Wschodniego CesarstwaikonoklazmBizancjum w VIII w.cezaropapizmLeon III Izauryjczykcaesaropapismświat chrześcijański a islam
researchProduct

Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of th…

2015

Rationale: The QUANTIFY study compared the approved dual bronchodilator QVA149 with the free-dose combination of tiotropium plus formoterol (TIO+FOR) regarding lung function, dyspnoea and health status in patients with moderate-to-severe COPD. This post-hoc analysis reported on the subgroup of pts without ICS background therapy. Methods: This blinded, triple-dummy 26-week study randomised patients to QVA149 110/50 µg OD or TIO 18 µg OD plus FOR 12 µg b.i.d. (1:1). ICS was allowed as background therapy. Endpoints included lung function (trough FEV1), dyspnoea (TDI) and health status (COPD Assessment Test, CAT). Results: Of the 934 pts randomised (QVA149 [N=476] or TIO+FOR [N=458]); 87.9% com…

COPDmedicine.medical_specialtyPediatricsbusiness.industrymedicine.drug_classrespiratory systemmedicine.diseaserespiratory tract diseasesBronchodilatorInternal medicinePost-hoc analysisCopd assessment testmedicineIn patientFormoterolOnce dailybusinessLung functionmedicine.drug5.1 Airway Pharmacology and Treatment
researchProduct

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study

2018

Roland Buhl,1 Carl-Peter Criée,2 Peter Kardos,3 Claus F Vogelmeier,4 Konstantinos Kostikas,5 Nadine S Lossi,6 Heinrich Worth7 1Pulmonary Department, Mainz University Hospital, Mainz, 2Department of Sleep and Respiratory Medicine, Evangelical Hospital Goettingen-Weende, Bovenden, 3Group Practice and Centre for Allergy, Respiratory and Sleep Medicine, Red Cross Maingau Hospital, Frankfurt am Main, 4Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany; 5WorldWide Medical Affairs Respiratory, Novartis Pharma AG, Basel, Switzerland;…

COPDmedicine.medical_specialtybusiness.industrymedicine.drug_classGeneral MedicineInternational Journal of Chronic Obstructive Pulmonary Diseasemedicine.diseaseClinical trial03 medical and health sciences0302 clinical medicinePrior Therapy030228 respiratory systemMaintenance therapyBronchodilatorInternal medicineCohortMedicineCorticosteroidObservational study030212 general & internal medicinebusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Salbutamol Transport and Deposition in the Upper and Lower Airway with Different Devices in Cats: A Computational Fluid Dynamics Approach

2021

Simple Summary Administration of inhaled salbutamol via metered-dose inhalers can effectively treat bronchoconstriction. Different devices are used for the delivery of this drug in cats, either in the hospital or at home, for long-term treatment. Effective drug administration may depend on the drug delivery device as well as patient cooperation. By using non-invasive computational fluid dynamics techniques, the impact of these devices on the deposition and transport of salbutamol particles in the cat airways was simulated and assessed. The results confirm a variable drug distribution depending on the device used. The percentage of particles reaching the lung was reduced when using spacers a…

Chronic bronchitisMaterials sciencefeline modelmedicine.drug_classbronchodilatorVeterinary medicineAirflowArticleChronic bronchitispressurized metered dose inhalerBronchodilatorSF600-1100medicineDeposition (phase transition)AsthmaLungGeneral Veterinaryrespiratory systemasthmamedicine.diseaseAsthmarespiratory tract diseasesmedicine.anatomical_structureQL1-991Feline modelSalbutamolchronic bronchitisAnimal Science and ZoologyPressurized metered dose inhalerAirwayCFDBronchodilatorZoologyBiomedical engineeringmedicine.drugAnimals
researchProduct

Conscious and unconscious identification of female anorectic patients in in-patient psychotherapy

2009

Women are up to ten times more likely to develop anorexia nervosa (AN) than men. Psychoanalytic explanations of this disparity generally emphasize female identification problems due to unresolved conflicts with maternal representations. Based on clinical observation, we identify a subtype of AN patients characterized, first, by consistent idealization of the father who needs the patient for the fulfilment of his own narcissistic needs and, second, by the patient's need to be idealized by the father due to suffering in connection with early emotional malnutrition on the part of the mother. To illustrate this hypothesis, we present the case of a well-educated young woman displaying unconsciou…

Clinical PsychologyMalnutritionEating disordersPsychotherapistUnconscious mindmedicineIdealizationAnorecticPsychoanalytic theoryPsychologymedicine.diseasePsychodynamicsCompetence (human resources)Psychodynamic Practice
researchProduct

The relaxant effects of cromakalim (BRL 34915) on human isolated airway smooth muscle

1992

Cromakalim (BRL 34915) is a potassium channel opener with therapeutic potential as a bronchodilator in asthma. Cromakalim (0.1–30 μmol/l) inhibited the spontaneous tone of human isolated bronchi n a concentration-related manner being nearly as effective as isoprenaline or theophylline. The order of relaxant potencies (expressed as -log10 IC50 mol/l; mean ±SEM) was isoprenaline (7.29 ± 0.27; n = 8) > cromakalim (5.89 ± 0.12; n = 7) > theophylline (4.07 ±0.13; n = 10). In human bronchi where tone had been raised by addition of histamine (0.1 mmol/l), acetylcholine (0.1 mmol/l) or leukotriene D4 (LTD4, 0.1 μmol/l), the relaxant effect of cromakalim was substantially reduced. Cromakalim suppres…

CromakalimMuscle RelaxationBronchiPharmacologyGlibenclamidechemistry.chemical_compoundTheophyllineIsoprenalinemedicineHumansBenzopyransDrug InteractionsPyrrolesPharmacologyTetraethylammoniumIsoproterenolMuscle SmoothGeneral MedicineAcetylcholineBronchodilator AgentschemistryAnesthesiaSRS-APotassium channel openermedicine.symptomCromakalimHistamineAcetylcholineHistamineMuscle contractionmedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim

1996

1. SCA40 (0.1 nM-0.1 mM) produced concentration-dependent suppression of the spontaneous tone of human isolated bronchus (-log EC50 = 6.85 +/- 0.09; n = 10) and reached a maximal relaxation similar to that of theophylline (3 mM). The potency (-log EC50 values) of SCA40 compared to other relaxants was rolipram (7.44 +/- 0.12; n = 9) > SCA40 > or = levcromakalim (6.49 +/- 0.04; n = 6) > SKF94120 (5.87 +/- 0.10; n = 9). 2. When tested against the activity of the isoenzymes of cyclic nucleotide phosphodiesterase (PDE) isolated from human bronchus, SCA40 proved highly potent against PDE III (-log IC50 = 6.47 +/- 0.16; n = 4). It was markedly less potent against PDE IV (4.82 +/- 0.18; n = 4) and …

Cromakalimmedicine.medical_specialtyCardiotonic AgentsNeutrophilsLeukotriene B4Muscle Relaxationchemistry.chemical_elementBronchiIn Vitro TechniquesCalciumPharmacologyLeukotriene B4chemistry.chemical_compound3'5'-Cyclic-GMP PhosphodiesterasesSuperoxidesInternal medicinemedicineHumansBenzopyransPyrrolesRolipramCyclic Nucleotide Phosphodiesterases Type 5PharmacologyCyclic nucleotide phosphodiesterasePhosphoric Diester HydrolasesSuperoxideAnti-Inflammatory Agents Non-SteroidalElastaseImidazolesN-Formylmethionine leucyl-phenylalanineCyclic Nucleotide Phosphodiesterases Type 3PyrrolidinonesBronchodilator AgentsCyclic Nucleotide Phosphodiesterases Type 4N-Formylmethionine Leucyl-PhenylalanineEndocrinologychemistry3'5'-Cyclic-AMP PhosphodiesterasesPyrazinesCalciumLeukocyte ElastaseRolipramCromakalimResearch Articlemedicine.drugBritish Journal of Pharmacology
researchProduct

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease

2009

After more than two decades of research into phosphodiesterase 4 (PDE4) inhibitors, roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]-benzamide) may become the first agent in this class to be approved for patient treatment worldwide. Within the PDE family of 11 known isoenzymes, roflumilast is selective for PDE4, showing balanced selectivity for subtypes A-D, and is of high subnanomolar potency. The active principle of roflumilast in man is its dichloropyridyl N-oxide metabolite, which has similar potency as a PDE4 inhibitor as the parent compound. The long half-life and high potency of this metabolite allows for once-daily, oral administration of a single, 500…

CyclopropanesPulmonary and Respiratory MedicinePhosphodiesterase Inhibitorsmedicine.drug_classDrug Evaluation PreclinicalAdministration OralAminopyridinesInflammationPharmacologyPulmonary Disease Chronic ObstructiveCOPD; Inflammation; Oral therapy; Phosphodiesterase 4; Preclinical pharmacology; RoflumilastBronchodilatormedicineAnimalsHumansCOPDPharmacology (medical)RoflumilastPhosphodiesterase 4InflammationCOPDLungOral therapybusiness.industryAnti-Inflammatory Agents Non-SteroidalBiochemistry (medical)medicine.diseasePulmonary hypertensionObstructive lung diseasemedicine.anatomical_structureTolerabilityBenzamidesImmunologyPhosphodiesterase 4 InhibitorsPreclinical pharmacologymedicine.symptombusinessRoflumilastmedicine.drug
researchProduct